Details for New Drug Application (NDA): 219585

NDA 219585 describes ZINC SULFATE, which is a drug marketed by Abraxis Pharm, Am Regent, Apotex, Aspiro, Fresenius Kabi Usa, Gland, Nivagen Pharms Inc, Rk Pharma, Somerset Theraps Llc, and Zydus Pharms, and is included in ten NDAs. It is available from ten suppliers. Additional details are available on the ZINC SULFATE profile page.

The generic ingredient in ZINC SULFATE is zinc sulfate. There are thirty-eight drug master file entries for this compound. Ten suppliers are listed for this compound. Additional details are available on the zinc sulfate profile page.

Summary for 219585

Tradename:	ZINC SULFATE
Applicant:	Aspiro
Ingredient:	zinc sulfate
Patents:	0

Pharmacology for NDA: 219585

Physiological Effect

Decreased Copper Ion Absorption

Medical Subject Heading (MeSH) Categories for 219585

Astringents

Suppliers and Packaging for NDA: 219585

Tradename	Generic Name	Dosage	NDA	Application Type	Supplier	National Drug Code	Package Code	Package
ZINC SULFATE	zinc sulfate	SOLUTION;INTRAVENOUS	219585	ANDA	Camber Pharmaceuticals, Inc.	31722-453	31722-453-31	25 VIAL in 1 CARTON (31722-453-31) / 10 mL in 1 VIAL (31722-453-10)
ZINC SULFATE	zinc sulfate	SOLUTION;INTRAVENOUS	219585	ANDA	Camber Pharmaceuticals, Inc.	31722-454	31722-454-31	25 VIAL in 1 CARTON (31722-454-31) / 10 mL in 1 VIAL (31722-454-10)

Profile for product number 001

Active Rx/OTC/Discontinued:	RX	Dosage:	SOLUTION;INTRAVENOUS			Strength	EQ 10MG BASE/10ML (EQ 1MG BASE/ML)
Approval Date:	May 1, 2025	TE:	AP	RLD:	No

Profile for product number 002

Active Rx/OTC/Discontinued:	RX	Dosage:	SOLUTION;INTRAVENOUS			Strength	EQ 25MG BASE/5ML (EQ 5MG BASE/ML)
Approval Date:	May 1, 2025	TE:	AP	RLD:	No

Profile for product number 003

Active Rx/OTC/Discontinued:	RX	Dosage:	SOLUTION;INTRAVENOUS			Strength	EQ 30MG BASE/10ML (EQ 3MG BASE/ML)
Approval Date:	May 1, 2025	TE:	AP	RLD:	No

Complete Access Available with Subscription